Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2025 New trial record